The nuclear export protein XPO1—from biology to targeted therapy
AS Azmi, MH Uddin, RM Mohammad - Nature reviews Clinical oncology, 2021 - nature.com
Abstract Exportin 1 (XPO1), also known as chromosome region maintenance protein 1,
plays a crucial role in maintaining cellular homeostasis via the regulated export of a range of …
plays a crucial role in maintaining cellular homeostasis via the regulated export of a range of …
XPO1-dependent nuclear export as a target for cancer therapy
NG Azizian, Y Li - Journal of hematology & oncology, 2020 - Springer
Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large
molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for …
molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for …
[HTML][HTML] Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE …
T Martin, SZ Usmani, JG Berdeja, M Agha… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of
ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory …
ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory …
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma …
JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak… - The Lancet, 2021 - thelancet.com
Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene
autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation …
autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation …
[HTML][HTML] Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma
Background Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-
cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of …
cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of …
[HTML][HTML] Oral selinexor–dexamethasone for triple-class refractory multiple myeloma
A Chari, DT Vogl, M Gavriatopoulou… - … England Journal of …, 2019 - Mass Medical Soc
Background Selinexor, a selective inhibitor of nuclear export compound that blocks exportin
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins …
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins …
The multiple myelomas—current concepts in cytogenetic classification and therapy
SK Kumar, SV Rajkumar - Nature reviews Clinical oncology, 2018 - nature.com
Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …
malignancies and predominantly affects older individuals (with a median age at diagnosis of …
The intersection of COVID-19 and cancer: signaling pathways and treatment implications
The outbreak of the novel coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a serious public health …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as a serious public health …
FDA-approved drugs for hematological malignancies—the last decade review
A Sochacka-Ćwikła, M Mączyński, A Regiec - Cancers, 2021 - mdpi.com
Simple Summary Hematological malignancies are diseases involving the abnormal
production of blood cells. The aim of the study is to collect comprehensive information on …
production of blood cells. The aim of the study is to collect comprehensive information on …
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies
demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors …
demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors …